Randomised Phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic CRC with either KRAS WT or G13D mutation. ICE CREAM: The Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation Among Patients with G13D Mutation
Latest Information Update: 09 Feb 2023
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms AGITG ICECREAM; ICE CREAM
- 23 Mar 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
- 12 Oct 2017 Status changed from active, no longer recruiting to completed.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology